国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

USEUROPEAFRICAASIA 中文雙語(yǔ)Fran?ais
Business
Home / Business / Industries

Foreign interest grows in aging society

By LIU JIE | China Daily | Updated: 2013-03-30 01:56

Foreign interest grows in aging society

World headquarters of Pfizer Inc in New York.Provided to China Daily

Liu Zhanglin has been working in China's pharmaceutical industry — especially the consumer healthcare and traditional Chinese medicine segments — for nearly three decades.

The industry veteran forecasts the nation's consumer healthcare sector will grow at a steady 10 percent over the next three to five years.

Bruce Liu, a strategy consultant with equally rich experience in the international pharmaceutical industry, is even more optimistic.

He suggests that by 2015, the sector will be worth more than 100 billion yuan ($16.01 billion) from its current 60 billion yuan, and will be growing at around 20 percent annually.

But both professionals share one view — that the sector is likely to become one of China's most lucrative.

Liu Zhanglin, vice-president of China Chamber of Commerce for Import & Export of Medicines & Health Products, is slightly more conservative with his growth forecasts, but predicts the sector will accelerate at a higher rate than the nation's GDP growth, given the country's aging population.

Bruce Liu, a partner and co-head of the pharma and healthcare practice at Roland Berger Strategy Consultants, said one of the most striking aspects of China's fast-growing consumer healthcare sector is the number of multinational pharmaceutical companies competing in an attempt to cash in on market.

Pfizer Inc, the world's largest drugmaker by sales, for instance, announced at the end of January that it planned to target the China healthcare market with launch of a new supplement series.

"Pronutrients" is an advanced line of Pfizer's famous multivitamin brand "Centrum" and has been promoted to China only after its launch in the home market, the United States.

Pfizer now has several mature supplement brands in China, another being "Caltrate".

Related Readings

'Best time' to invest in healthcare industry

Healthcare reform improves equal access

Looking abroad for healthcare

China becoming healthcare R&D hub

Previous Page 1 2 3 4 5 Next Page

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
台湾省| 汶上县| 塔河县| 郁南县| 桃园市| 盐城市| 宜昌市| 芦山县| 海口市| 白玉县| 渝北区| 衡山县| 长沙市| 奉新县| 烟台市| 武义县| 杭锦后旗| 五常市| 武隆县| 德阳市| 蕲春县| 上虞市| 固阳县| 乌拉特后旗| 信宜市| 新昌县| 阜新| 山丹县| 枣阳市| 达拉特旗| 富蕴县| 唐河县| 平谷区| 钦州市| 灵丘县| 开阳县| 友谊县| 望谟县| 东乌珠穆沁旗| 务川| 内黄县|